
Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

is a genetic disease associated with defects in neurotransmitter synthesis, resulting in life-limiting motor and autonomic dysfunction, developmental delay, and premature death.¹⁻³



Many of the most common symptoms of AADC deficiency can also be attributed to a number of other conditions such as cerebral palsy and epilepsy, resulting in potential misdiagnosis.^{2,3,5-7}

Diagnostic tests that identify AADC deficiency²

Following this diagnostic process can help diagnose AADC deficiency²

a) Genetic Testing	 b) Plasma enz activity ass 		 c) CSF neurotransmitter metabolite panel
Interpret ²			
1. Genetic tes	ting (Mutation(s) in the DDC gene)	
2. Plasma		3. CSF	
		☆ HIGH LEVELS OF	
		3-OMD	
		L-dopa	
•			
Decreased	AND/OR	5-HTP	
AADC	AND/OR	5-HTP	
	AND/OR		
AADC	AND/OR	Source Low Levels of	
AADC	AND/OR	VIEVELS OF 5-HIAA	

? Other diagnostic tests that may be helpful²

- > Blood level measurement of 3-OMD
- > Urinary organic acid analysis

Consensus guidelines recommend confirming an AADC deficiency diagnosis with a genetic test. If genetic diagnosis is performed as the first step, functional confirmation should be completed by measuring AADC enzyme activity in plasma and/or neurotransmitter metabolites in CSF.²

3-OMD=3-O-methyldopa; 5-HIAA=5-hydroxyindoleacetic acid; 5-HTP=5-hydroxytryptophan; CSF=cerebrospinal fluid; DDC=dopa decarboxylase; HVA=homovanillic acid; L-dopa=L-3,4-dihydroxyphenylalanine; MHPG=3-methoxy-4-hydroxyphenylglycol; VLA=vanillactic acid.

References: 1. Manegold C, Hoffmann GF, Degen I, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. *J Inherit Metab Dis.* 2009;32(3):371-380. **2.** Wassenberg T, Molero-Luis M, Jeltsch K, et al. Consensus guideline for the diagnosis and treatment of aromatic I-amino acid decarboxylase (AADC) deficiency. *Orphanet J Rare Dis.* 2017;12(1):12. doi: 10.1186/s13023-016-0522-z. **3.** Brun L, Ngu LH, Keng WT, et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology. 2010;75(1):64-71. **4.** Garcia-Cazorla A, Duarte S, Serrano M, et al. Mitochondrial diseases mimicking neurotransmitter defects. *Mitochondrion.* 2008;8(3):273-278. **5.** Krigger KW. Cerebral palsy: an overview. *Am Fam Physician.* 2006;73(1):91-100. **6.** Ng J, Papandreou A, Heales SJ, et al. Monoamine neurotransmitter disorders—clinical advances and future perspectives. *Nat Rev Neurol.* 2015;11(10):567-584. **7.** Kurian MA, Dale RC. Movement disorders presenting in childhood. *Continuum (Minneap Minn).* 2016;22(4 Movement Disorders):1159-1185.

©2019 PTC Therapeutics. All rights reserved. MAT-AADC-0236. PTC Therapeutics ACN: 635 417 711 ABN: 19 635 417 711 Address: Level 11, 500 Collins Street, Melbourne VIC 3000. Date of Preparation: April 2022. zz2_1307

